Scpharmaceuticals Inc Asset Resilience Ratio
Scpharmaceuticals Inc asset resilience ratio. Scpharmaceuticals Inc (SCPH) has an Asset Resilience Ratio of 0.39% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Scpharmaceuticals Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Scpharmaceuticals Inc (2020–2024)
Asset resilience ratio of Scpharmaceuticals Inc from 2020 to 2024. This chart shows how Scpharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read Scpharmaceuticals Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Scpharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Scpharmaceuticals Inc (SCPH) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $354.00K | 0.39% |
| Total Liquid Assets | $354.00K | 0.39% |
Asset Resilience Insights
- Limited Liquidity: Scpharmaceuticals Inc maintains only 0.39% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Scpharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Scpharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Scpharmaceuticals Inc Asset Resilience Ratio by Year (2020–2024)
Scpharmaceuticals Inc asset resilience ratio by year from 2020 to 2024. The table below shows the annual Asset Resilience Ratio data for Scpharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.95% | $1.02 Million | $107.52 Million | -29.96pp |
| 2023-12-31 | 30.91% | $29.20 Million | $94.48 Million | -7.04pp |
| 2022-12-31 | 37.94% | $47.12 Million | $124.19 Million | +36.67pp |
| 2021-12-31 | 1.28% | $1.01 Million | $79.04 Million | -29.24pp |
| 2020-12-31 | 30.52% | $33.28 Million | $109.05 Million | -- |
About Scpharmaceuticals Inc
scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and … Read more